title: Remission of nonparaneoplastic autoimmune retinopathy after minimal steroid treatment.
abstract: OBJECTIVE
  To describe the clinical findings in a patient demonstrating recovery from nonparaneoplastic autoimmune retinopathy after a minimal course of steroid treatment.
  
  
  METHODS
  Clinical presentation was documented, and paraclinical tests were obtained using Humphrey automated perimetry for visual fields, Western blotting for antiretinal antibodies, and electroretinography for evaluation of rod and cone function.
  
  
  RESULTS
  Initial presentation revealed marked visual field deficits, electroretinographic dysfunction, and the presence of α-enolase autoantibodies. After a brief course of oral corticosteroids, the patient demonstrated improvement in visual fields, disappearance of α-enolase autoantibodies, partial recovery of the cone on-response, and complete recovery of the rod response.
  
  
  CONCLUSIONS
  This case is distinguished from previous reports by the rapidity and degree of recovery, the brevity of treatment required, and the unique electroretinographic recovery pattern with concomitant disappearance of α-enolase autoantibodies. These findings suggest a pathologic role for α-enolase autoantibodies in autoimmune rod bipolar cell dysfunction. Identification of other cases exhibiting such improvements and associated autoantibody activity may expand our understanding of nonparaneoplastic autoimmune retinopathy disease pathogenesis.
authors.affiliation: *Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; †Department of Ophthalmology, Ivey Eye Institute, Western University, London, Ontario, Canada; ‡Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada; and §Department of Clinical Neurological Sciences, Western University, London, Ontario, Canada.
authors.forename: Lulu L C D
authors.initials: LL
authors.lastname: Bursztyn
authors.forename: Jillian C
authors.initials: JC
authors.lastname: Belrose
authors.forename: Stuart G
authors.initials: SG
authors.lastname: Coupland
authors.forename: J Alexander
authors.initials: JA
authors.lastname: Fraser
authors.forename: Alain A
authors.initials: AA
authors.lastname: Proulx
mesh_terms: D000284:Administration, Oral; D001323:Autoantibodies / Q000276:immunology*; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D001706:Biopsy; D004305:Dose-Response Relationship, Drug; D004596:Electroretinography; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D010257:Paraneoplastic Syndromes; D011241:Prednisone / Q000008:administration & dosage*; D012074:Remission Induction; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D041623:Tomography, Optical Coherence; D014794:Visual Fields
chemical_list: D001323:Autoantibodies; D005938:Glucocorticoids; D011241:Prednisone